Trial 5GYN-17-1


A Phase III, multicenter, randomized study of Atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab for patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Biological Response Modifier, Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Lynda Roman, M.D.
Other Trial Staff:  Lusine Raddatz, D.M., Grace Facio, Coordinator, Marissa Aldana, D.M., Apoorva Vishwanath, D.M., Alix Cohen, R.N., Stacie DeFilio, Coordinator, Brigitte Torres, Coordinator, Sophie Miehl, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.